Plain-English translation of NCT07691125 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a Phase IV study testing recombinant human growth hormone injection (rhGH) in adults with short bowel syndrome (SBS) who need parenteral nutrition support. Researchers want to see if this medication can help your body absorb nutrients better and reduce your dependence on intravenous nutrition. All participants will receive the same treatment during the study.
Short bowel syndrome makes it difficult for your body to absorb enough nutrients from food because part of your small intestine is missing or doesn't work properly. This medication may help improve nutrient absorption and potentially reduce how much time you spend on parenteral nutrition support.
You likely qualify if…
You likely don't qualify if…
You will start with a 2-week run-in phase to establish a baseline, then receive growth hormone injections for 4 weeks while your response is carefully monitored. After that, you'll enter a 52-week follow-up period where researchers track your progress, safety, and how well the treatment is working. Throughout the study, you'll have regular clinic visits for blood tests and check-ins.
AI-generated summary from trial data · Sep 3, 2026 · Not medical advice
China